Fig. 3
From: A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients
Outer membrane protein F/I hybrid vaccine (OprF/I)-specific IgG antibody geometric mean titers (GMT) (U/ml) (intention-to-treat (ITT) population). Note, on day 14 (primary endpoint), there was a statistically significant difference in the OprF/I-specific IgG antibody titer in all IC43 groups compared with placebo (all P < 0.0001). In addition, there were statistically significant differences between all IC43 groups versus placebo on days 28, 42, 56, and 70 (P ≤ 0.0119). At baseline (day 0), 25 subjects had a detectable OprF/I IgG titer >350 U/ml; none of these patients had a baseline infection. *Statistically significant difference between 200 μg and 100 μg IC43 with adjuvant (P = 0.0344). †Two outliers representing measurements in six subjects (11,582 and 7,935 U/ml). ‡Optional visit. w/o without aluminum hydroxide adjuvant, ANOVA analysis of variance